Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Harald Duerr

Christian Klein

Joerg Thomas Regula

Sabine Imhof-Jung

Petra Rueger

Wolfgang Schaefer

Michael Molhoj

Ulrich Goepfert

Laurent Lariviere

Pablo Umana

Sebastian Fenn

Alexander Bujotzek

Peter Bruenker

Joerg Zielonka

Christine Trumpfheller

Moritz Rapp

Kay-Gunnar Stubenrauch

Matthias Rueth

Frank Herting

Marine Le Clech

Ekkehard Moessner

Guy Georges

Erhard Kopetzki

Ulrich Brinkmann

Pablo Umaña

Juergen Michael Schanzer

Maria Amann

Andreas Schaubmar

Rebecca Croasdale

Johannes Sam

Roland Staack

Wilma Lau

Katharina Wartha

Rebecca Croasdale-Wood

Laurene Pousse

Thomas Kraft

Estelle Marrer-Berger

Stéphane LeClair

Juergen Peter Bachl

Carina Cantrill

Janine Faigle

Dietrich Tuerck

Stephane Leclair

Eva Carina Sum

Sabine Bertl

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-FAP clone 212

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules targeting OX40 and FAP

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

The present invention is directed to methods comprising the use of hydroxyapatite chromatography to separate a bispecific antibody from a solution that also comprises one or more byproducts specific to bispecific antibody production. Byproducts specific to the production of bispecific antibodies (bispecific antibody specific byproducts, 'BASB') include fragments of the bispecific antibody and heavier molecular weight variants of the antibody, wherein the fragment and/or variant comprises an Fc domain but does not exhibit affinity for the two different epitopes and/or antigens as exhibited by the desired bispecific antibody. Thus, the methods of the present invention comprise the separation of a bispecific antibody from one or more of its BASB. The hydroxyapatite chromatography methods of the invention may be used alone or may be further combined with standard purification processes and unit operations as is known in the art to achieve any level of purity of bispecific antibody necessary, e.g., for therapeutic and/or diagnostic applications.

Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography

The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies

Growing community of inventors

Starnberg, Germany

Harald Duerr